Paul A. Volberding
WASHINGTON — Infectious Disease News and Healio.com are onsite at IDWeek 2019 to provide live coverage of the conference, held from Oct. 2 to 6.
“IDWeek is always a great opportunity to stay in touch with the many rapidly changing issues affecting the ID community,” said Infectious Disease News Chief Medical Editor Paul A. Volberding, MD, professor of medicine and director of the AIDS Research Institute at the University of California, San Francisco. “I’m especially interested in learning more about strategies to facilitate new antibiotic drug development while at the same time discouraging inappropriate uses that set the stage for resistance selection. And on the HIV front, continuing efforts to use our powerful tools to bring an end to the epidemic.”
IDN staff will provide readers with expert video perspectives, reports on late-breaking clinical trial results, industry news and IDWeek-centric newswires featuring top headlines from the conference.
For the latest news throughout the week, visit our IDWeek meeting page. To begin your IDWeek journey early, check out some stories IDN covered last year:
Antiseptic prevents therapy dogs from spreading MRSA to pediatric cancer patients
Researchers found that a low-cost cleaning procedure could prevent therapy dogs from spreading MRSA among pediatric cancer patients — presenting a possible solution to the danger that therapy animals pose to at-risk patients. Read more.
WhatsApp alert improves real-time antimicrobial stewardship program
A hospital antimicrobial stewardship program in Mexico City incorporated a smartphone messaging app as a fundamental part of real-time surveillance, improving the appropriate use of antibiotics, decreasing bacterial resistance and saving money, according to study findings. Read more.
VIDEO: Lessons learned from a year laden with foodborne outbreaks
In this video, Robert Tauxe, MD, MPH, director of the CDC’s Division of Foodborne, Waterborne and Environmental Diseases, emphasizes the critical role of clinicians in preventing and diagnosing foodborne outbreaks. Watch.
LEAP 2 study demonstrates safety, efficacy of oral lefamulin for CABP
A 5-day course of oral lefamulin is noninferior to 7 days of oral moxifloxacin for the treatment of community-acquired bacterial pneumonia, according to results from a second phase 3 trial. Read more. Editor’s note: Lefamulin (Xenleta, Nabriva) has since been approved by the FDA.
Study spotlights sex differences in achievement and rank in ID faculty
Analyzing a database of physicians in the United States with faculty appointments at medical schools, Jennifer Manne-Goehler, MD, DSc, MSc, infectious disease fellow at Massachusetts General Hospital, and colleagues found that women were far less likely than men to achieve the rank of full professor and appeared as first or last author on scientific publications about half as often. Read more.